Physician profile
Aileen Ingal
NPI 1205035516
$2,258.51
in general payments reported to CMS, 2019-2025
18 companies · $406 in 2025
The $406 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43.89 · 2020: $156 · 2021: $419 · 2022: $344 · 2023: $470 · 2024: $420 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,295.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $598.02 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $404.57 | 2021-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $248.12 | 2020-2022 | |
| Pfizer INC. | $191.85 | 2021-2025 | |
| Amgen INC. | $184.88 | 2019-2025 | Repatha, Repatha |
| Lexicon Pharmaceuticals, INC. | $120.16 | 2023-2024 | Inpefa |
| Amarin Pharma, INC. | $113.24 | 2021-2023 | |
| Abbott Laboratories | $94.19 | 2022-2024 | Cardiomems, Jot Dx |
| Actelion Pharmaceuticals US, INC. | $55.61 | 2024-2025 | Uptravi, Opsumit |
| Merck Sharp & Dohme LLC | $38.28 | 2023 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $35.90 | 2021-2024 | Farxiga |
| Novo Nordisk INC | $34.05 | 2024-2025 | Ozempic, Wegovy |
| Abiomed | $33.29 | 2023 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.33 | 2020 | |
| Esperion Therapeutics, INC. | $25.45 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akcea Therapeutics, INC. | $22.54 | 2021 | |
| Philips North America LLC | $18.53 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Kowa Pharmaceuticals America, INC. | $12.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aileen Ingal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.